Compare TAP & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAP | DVA |
|---|---|---|
| Founded | 1873 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Misc Health and Biotechnology Services |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.1B |
| IPO Year | N/A | 2002 |
| Metric | TAP | DVA |
|---|---|---|
| Price | $42.60 | $150.04 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $50.31 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 2.9M | 730.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $0.85 | $3.80 |
| Revenue Next Year | $0.14 | $3.04 |
| P/E Ratio | ★ N/A | $15.39 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $42.08 | $101.00 |
| 52 Week High | $63.40 | $159.42 |
| Indicator | TAP | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 28.89 | 55.82 |
| Support Level | N/A | $146.00 |
| Resistance Level | $47.36 | $150.69 |
| Average True Range (ATR) | 1.10 | 4.69 |
| MACD | -0.61 | -1.67 |
| Stochastic Oscillator | 7.09 | 29.63 |
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.